The FDA has agreed that Spectrum Pharma can remove from the labelling of Zevalin (ibritumomab tiuxetan) a requirement for a...
Spectrum Pharmaceuticals will acquire from Bayer Healthcare the licensing rights to market Zevalin (ibritumomab tiuxetan) injection for intravenous use for...